Clinical Trial Updates17 Jun 2025
Spyre Therapeutics announced positive interim Phase 1 results for SPY002 and SPY072, two investigational, extended half-life monoclonal antibodies tar...
Clinical Trial Updates17 Jun 2025
Spyre Therapeutics announced that it will report interim results from Phase 1 healthy volunteer trials for its SPY002 program, a novel half-life exten...
Clinical Trial Updates16 Jun 2025
KalVista Pharmaceuticals announced positive data from the KONFIDENT-S trial at the EAACI Congress 2025, showcasing sebetralstat's efficacy as an oral,...
Clinical Trial Updates13 Jun 2025
ITM Isotope Technologies Munich SE announced that it will present further analysis from its completed Phase 3 COMPETE trial at the SNMMI 2025 annual m...
Clinical Trial Updates13 Jun 2025
Novo Nordisk announced its advancement of both subcutaneous and oral amycretin into phase 3 clinical development for weight management. This decision ...
Clinical Trial Updates13 Jun 2025
Johnson & Johnson announced positive Phase 1b data for bleximenib, a menin inhibitor, in combination with venetoclax and azacitidine for acute myeloid...
Clinical Trial Updates12 Jun 2025
UCB announced three-year data from Phase 3 trials and open-label extensions showing sustained efficacy of BIMZELX® (bimekizumab) in treating adults wi...
Clinical Trial Updates12 Jun 2025
A clinical study published in the Journal of Wound Care demonstrates that MolecuLight's i:X® device significantly improves outcomes for deep sternal w...
Clinical Trial Updates12 Jun 2025
Schrödinger announced positive initial clinical data from a Phase 1 study of SGR-1505, an oral MALT1 inhibitor, in patients with relapsed/refractory B...
Clinical Trial Updates12 Jun 2025
Vaxart, Inc. announced positive topline results from a Phase 1 clinical trial evaluating its second-generation oral pill norovirus vaccine. The trial...
Clinical Trial Updates11 Jun 2025
BioInvent International AB announced positive Phase 1 data for its drug candidate BI-1206, used in combination with Merck's KEYTRUDA (pembrolizumab), ...
Clinical Trial Updates11 Jun 2025
Harmony Biosciences announced positive preclinical data for BP1.15205, a novel orexin 2 receptor (OX2R) agonist, demonstrating significant wake-promot...
Clinical Trial Updates11 Jun 2025
Kazia Therapeutics announced the publication of preclinical research in Molecular Cancer Therapeutics demonstrating paxalisib's potential to overcome ...
Clinical Trial Updates11 Jun 2025
A randomized clinical trial published in JAMA Pediatrics demonstrates that EEG-guided anesthesia using Masimo SedLine® Brain Function Monitoring signi...
Clinical Trial Updates11 Jun 2025
Travere Therapeutics announced it will present new data on FILSPARI (sparsentan) at the International Podocyte Conference. Data from the Phase 2 SPAR...
Clinical Trial Updates10 Jun 2025
Envoy Medical announced positive one-month follow-up results from the first stage of its pivotal clinical trial for the fully implanted Acclaim® Cochl...
Clinical Trial Updates10 Jun 2025
Novo Nordisk announced it will present new data at the American Diabetes Association (ADA) 85th Scientific Sessions in June 2025. This includes Phase...
Clinical Trial Updates23 May 2025
Actuate Therapeutics announced positive topline Phase 2 data for elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line metasta...
Clinical Trial Updates23 May 2025
Adagene announced updated Phase 1b/2 data for its anti-CTLA-4 antibody, Muzastotug (ADG126), in combination with pembrolizumab, in patients with micro...
Clinical Trial Updates23 May 2025
Alligator Bioscience announced the presentation of biomarker data from its OPTIMIZE-1 clinical trial at the 2025 ASCO Annual Meeting. OPTIMIZE-1 is a ...
Clinical Trial Updates23 May 2025
Ascentage Pharma announced positive clinical data for lisaftoclax, a Bcl-2 inhibitor, and alrizomadlin, an MDM2-p53 inhibitor. Data from a Phase 1b/2...
Clinical Trial Updates23 May 2025
Astria Therapeutics announced that it will present safety and efficacy data from Phase 1a and 1b/2 clinical trials of navenibart, a monoclonal antibod...
Clinical Trial Updates23 May 2025
Autobahn Therapeutics announced positive Phase 1 clinical trial results for ABX-002, a novel thyroid hormone beta receptor (TRβ) selective agonist, at...
Clinical Trial Updates23 May 2025
Avidicure announced it will present preclinical data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data highlights AVC...
Clinical Trial Updates23 May 2025
Bicara Therapeutics announced updated interim data from a Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab for first-lin...
Clinical Trial Updates23 May 2025
Bicycle Therapeutics announced the presentation of two abstracts at the 2025 ASCO Annual Meeting, showcasing preliminary results from their Phase 1/2 ...
Clinical Trial Updates23 May 2025
Biodesix announced new data from the INSIGHT study (NCT03289780) on the VeriStrat® Host Immune Classifier (HIC) test, to be presented at the 2025 ASCO...
Clinical Trial Updates23 May 2025
Boehringer Ingelheim will present data from two early-stage clinical trials investigating their SIRPα inhibitors, BI 765063 and BI 770371, at the 2025...
Clinical Trial Updates23 May 2025
Boehringer Ingelheim announced that it will present new clinical data from two early-stage trials investigating SIRPα inhibitors at the 2025 ASCO Annu...
Clinical Trial Updates23 May 2025
Bristol Myers Squibb announced the presentation of data from over 80 studies at the 2025 ASCO Annual Meeting. The data covers more than 20 cancer typ...
Clinical Trial Updates23 May 2025
Roche announced two-year follow-up data from the Phase III STARGLO study, showing a 40% improvement in overall survival (OS) for patients with relapse...
Clinical Trial Updates23 May 2025
CytoSorbents Corporation announced results from a real-world data analysis presented at EuroPCR 2025, showing that its CytoSorbents therapy significan...
Clinical Trial Updates23 May 2025
Daiichi Sankyo announced positive late-breaking data from two phase 3 trials, DESTINY-Breast09 and DESTINY-Gastric04, highlighting ENHERTU (trastuzuma...
Clinical Trial Updates23 May 2025
EMD Serono announced the presentation of new oncology data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Key highlights in...
Clinical Trial Updates23 May 2025
Exact Sciences announced the presentation of ten abstracts at the 2025 ASCO Annual Meeting, showcasing new data on its Oncodetect MRD test, multi-canc...
Clinical Trial Updates23 May 2025
Exelixis announced positive results from the Phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with immune checkpoint inhibitors fo...
Clinical Trial Updates23 May 2025
Genmab announced it will present new data at the 2025 ASCO Annual Meeting, focusing on its late-stage oncology portfolio. Key highlights include the ...
Clinical Trial Updates23 May 2025
Guardant Health announced that it and its collaborators will present data from over 19 studies at the 2025 ASCO Annual Meeting. These studies highlig...
Clinical Trial Updates23 May 2025
HUTCHMED announced that new data from several clinical studies of its compounds, including savolitinib, ranosidenib, fruquintinib, and surufatinib, wi...
Clinical Trial Updates23 May 2025
Hologic announced new data on the Breast Cancer Index® (BCI®) test, to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Me...
